StreetInsider.com News Articles

Form 8-K MARAVAI LIFESCIENCES For: Jun 02

Wed, 03 Jun 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260603/26596014.html

Form 8-K MARAVAI LIFESCIENCES For: Jun 02

Wed, 03 Jun 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260603/26596014.html

Maravai LifeSciences refinances debt, reduces principal by $92.9 million

Wed, 03 Jun 2026 08:30:42 -0400

Maravai LifeSciences Holdings Inc. (NASDAQ: MRVI) announced that its subsidiaries entered into a new credit agreement providing a $150 million term loan facility and a $30 million revolving credit facility.

The company used borrowings from the new term loan facility and approximately $98.5 million of cash on hand to prepay outstanding borrowings under its previous credit agreement that was due in October 2027.

The refinancing reduces Maravai's long-term debt from approximately $242.9 million in outstanding principal to $150.0 million in outstanding principal. The new term loan extends the maturity date to June 2032 while maintaining access to additional liquidity through the revolving

Maravai LifeSciences refinances debt, reduces principal by $92.9 million

Wed, 03 Jun 2026 08:30:42 -0400

Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Wed, 03 Jun 2026 08:30:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility and a $30 million revolving credit facility.

Borrowings under the new term loan facility, together with approximately $98.5 million of cash on hand, were used to prepay outstanding borrowings under the Company’s prior credit agreement due October 2027.

The transaction reduces the Company’s long-term debt from approximately $242.9 million in aggregate outstanding

Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Wed, 03 Jun 2026 08:30:00 -0400

The transaction reduces the Company’s long-term debt from approximately $242.9 million in aggregate outstanding

Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Wed, 03 Jun 2026 08:30:00 -0400

The transaction reduces the Company’s long-term debt from approximately $242.9 million in aggregate outstanding

Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Wed, 03 Jun 2026 08:30:00 -0400

The transaction reduces the Company’s long-term debt from approximately $242.9 million in aggregate outstanding

Form 8-K MARAVAI LIFESCIENCES For: May 26

Fri, 29 May 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260529/26575480.html

Form 8-K MARAVAI LIFESCIENCES For: May 26

Fri, 29 May 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260529/26575480.html

Form 4/A MARAVAI LIFESCIENCES For: May 26 Filed by: LUCIER GREGORY T

Thu, 28 May 2026 18:49:00 -0400

si-local-file:///var/storage/secattach/20260528/26569187.html

Form 4/A MARAVAI LIFESCIENCES For: May 26 Filed by: LUCIER GREGORY T

Thu, 28 May 2026 18:49:00 -0400

si-local-file:///var/storage/secattach/20260528/26569187.html

Form 4 MARAVAI LIFESCIENCES For: May 26 Filed by: MIHAS CONSTANTINE S